Zai Lab Limited partner Bristol Myers Squibb announced the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer harboring a KRASG12C mutation, met the primary endpoint of progression-free survival and the key secondary endpoint of overall response rate as assessed by Blinded Independent Central Review at final analysis for these endpoints.
